Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose ruxolitinib in intermediate/high-risk polycythemia vera
ChiCTR2200064247Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in polycythemia vera (PV), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Complete remission, Partial remission and 4 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on ChiCTR2200064247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064247.